0001827672-23-000018.txt : 20230317 0001827672-23-000018.hdr.sgml : 20230317 20230317180230 ACCESSION NUMBER: 0001827672-23-000018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230315 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azamian Bobak R. CENTRAL INDEX KEY: 0001827672 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 23744180 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160 CITY: IRVINE STATE: CA ZIP: 92618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 4 1 wf-form4_167909053944482.xml FORM 4 X0306 4 2023-03-15 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001827672 Azamian Bobak R. C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 1 1 0 0 President/CEO and Board Chair Common Stock 2023-03-15 4 S 0 8000 13.79 D 1080536 I By the Bobak Azamian Living Trust established April 16, 2018 Common Stock 2023-03-15 4 M 0 11299 A 13049 D Common Stock 2023-03-16 4 S 0 791 13.43 D 12258 D Restricted Stock Units 2023-03-15 4 M 0 11299 0 D Common Stock 11299.0 33898 D The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.52 to $14.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholdingobligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Each RSU represents a contingent right to receive one share of the Company's common stock. RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. /s/ Leonard M. Greenstein, Attorney-in-Fact 2023-03-17